Literature DB >> 7550950

Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting.

J Apelqvist1, G Ragnarson-Tennvall, J Larsson, U Persson.   

Abstract

The purpose of this study was to analyze long-term costs for foot ulcers in diabetic patients. Patients were treated and followed prospectively by a foot care team. A retrospective economic analysis was performed of costs for 274 patients during 3 years from healing of an initial foot ulcer, with or without amputation. Costs were estimated for inpatient care, outpatient care, home care, and social service. The cost calculations include costs due to complications and disability related to the initial ulcer, costs related to recurrence of ulcer, and costs for prevention of new ulcers. Expected total present value cost per patient during 3 years of observation was $26,700 (U.S. dollars) for primary healed patients with critical ischemia and $16,100 for primary healed patients without critical ischemia. For patients who healed with an amputation, the corresponding costs were $43,100 after a minor amputation and $63,100 after a major amputation. When estimating the costs for diabetic foot ulcers, it is not sufficient to calculate short-term costs. Long-term costs are high, mainly due to the need for increased home care and social service, but also due to costs for recurrent ulcers and new amputations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550950     DOI: 10.1177/107110079501600702

Source DB:  PubMed          Journal:  Foot Ankle Int        ISSN: 1071-1007            Impact factor:   2.827


  26 in total

Review 1.  Applications of economic models in healthcare: the introduction of pioglitazone in Sweden.

Authors:  Freddie Henriksson
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  Cost-effective management of diabetic foot ulcers. A review.

Authors:  G Ragnarson-Tennvall; J Apelqvist
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

Review 3.  Interactive wound dressings. A practical guide to their use in older patients.

Authors:  C Hansson
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

Review 4.  Model-based evaluation of diabetic foot prevention strategies in Austria.

Authors:  Marion S Rauner; Kurt Heidenberger; Eva-Maria Pesendorfer
Journal:  Health Care Manag Sci       Date:  2005-11

5.  Economic evaluation of Vacuum Assisted Closure® Therapy for the treatment of diabetic foot ulcers in France.

Authors:  Sarah J Whitehead; Véronique L Forest-Bendien; Jean-Louis Richard; Serge Halimi; Georges Ha Van; Paul Trueman
Journal:  Int Wound J       Date:  2010-09-28       Impact factor: 3.315

6.  Botulinum toxin effects on gasatrocnemius strength and plantar pressure in diabetics with peripheral neuropathy and forefoot ulceration.

Authors:  Mary K Hastings; Michael J Mueller; David R Sinacore; Michael J Strube; Beth E Crowner; Jeffrey E Johnson; Brad R Racette
Journal:  Foot Ankle Int       Date:  2012-05       Impact factor: 2.827

7.  Cost-effectiveness of treating vascular leg ulcers with UrgoStart(®) and UrgoCell(®) Contact.

Authors:  Matthias Augustin; Katharina Herberger; Knut Kroeger; Karl C Muenter; Lisa Goepel; Reinhard Rychlik
Journal:  Int Wound J       Date:  2014-02-21       Impact factor: 3.315

8.  The cost effectiveness of Apligraf treatment of diabetic foot ulcers.

Authors:  W Ken Redekop; Joseph McDonnell; Paul Verboom; Kornelia Lovas; Zoltan Kalo
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 9.  Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.

Authors:  Astrid Langer; Wolf Rogowski
Journal:  BMC Health Serv Res       Date:  2009-07-10       Impact factor: 2.655

10.  Substantial reduction in the number of amputations among patients with diabetes: a cohort study over 16 years.

Authors:  Benjamin S B Rasmussen; Knud B Yderstraede; Bendix Carstensen; Ole Skov; Henning Beck-Nielsen
Journal:  Diabetologia       Date:  2015-11-22       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.